#China #Shanghai #Aphranel #MagiCConcept #CaHA

Aphranel at SAAM 2025: Revolutionizing Aesthetic Medicine

Aphranel, the original aesthetic brand from Shanghai Moyang Biotechnology, made a significant impact at the Saudi Arabia Aesthetic Medicine Scientific Congress (SAAM 2025), held on November 27, 2025, in Riyadh. This congress, known for its focus on innovations in aesthetic dermatology and plastic surgery, attracted over 2,500 professionals from various regions, solidifying Aphranel's commitment to integrating aesthetic technologies from China with global practices.

During this prestigious event, Aphranel unveiled its highly anticipated product, the MagiCCrystal CaHA filler, which harnesses advanced calcium hydroxylapatite (CaHA) technology. This innovative filler is designed to enhance facial contouring and rejuvenation, marking a notable entry for Chinese aesthetic products on an international platform.

Furthermore, Aphranel showcased its patented injection techniques: the ACD-MT (a continuous microsphere technology) and the PCD-ETT (a physical cross-linking gel technology). These approaches are engineered to achieve a balance between immediate volumization and long-term collagen regeneration, supporting precise degradation profiles and safety. The introduction of these techniques represents a step forward in enhancing patient outcomes and safety in aesthetic treatments.

The event featured live demonstrations by leading Chinese clinicians, Dr. Wang Wenting from Guangzhou Yestar and Dr. Chen Lorraine from Shanghai LELITE M. Dr. Wenting provided insights into refined injection layer selection and dosage control, while Dr. Chen shared a strategic framework for effective layering techniques. Their contributions not only enhanced practical learning but also garnered recognition from international professionals, highlighting the expertise present in China's aesthetic medical field.

In addition to the congress activities, Aphranel's team engaged with local aesthetic institutions for technical exchanges on regenerative materials and protocol design, positioning the MagiCCrystal CaHA as a platform for Sino-Saudi professional dialogue. This initiative underscores Aphranel's ambition to bridge knowledge and technology between China and Saudi Arabia, fostering cooperative advancement in aesthetic solutions.

The showcase at SAAM 2025 is a testament to the evolving capabilities of the Chinese cosmetics industry, from research and development to practical applications in the field. Aphranel plans to accelerate its international expansion by deepening collaborations and broadening market access, aiming to deliver more regenerative technologies and products from China to patients and clinicians worldwide.

As the company continues to innovate, it envisions becoming a pivotal contributor to the global aesthetic market, providing a significant 'Chinese impetus' for growth and development.

Pricing, availability, and regulatory status for MagiCCrystal CaHA will vary by market, with clinicians encouraged to adhere to local guidelines and protocols. Amidst this rapidly growing industry, Aphranel stands poised to make a lasting impact on the future of aesthetic medicine.